PRAN vs. GLTO, APM, INDP, NRSN, KALA, BIVI, VINC, AVTX, TLPH, and SLGL
Should you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include Galecto (GLTO), Aptorum Group (APM), Indaptus Therapeutics (INDP), NeuroSense Therapeutics (NRSN), KALA BIO (KALA), BioVie (BIVI), Vincerx Pharma (VINC), Avalo Therapeutics (AVTX), Talphera (TLPH), and Sol-Gel Technologies (SLGL). These companies are all part of the "medical" sector.
Alterity Therapeutics (NASDAQ:PRAN) and Galecto (NASDAQ:GLTO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, community ranking, dividends, valuation and earnings.
3.6% of Alterity Therapeutics shares are held by institutional investors. Comparatively, 14.2% of Galecto shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by insiders. Comparatively, 12.1% of Galecto shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Galecto has a consensus price target of $5.33, suggesting a potential upside of 651.07%. Given Galecto's higher possible upside, analysts plainly believe Galecto is more favorable than Alterity Therapeutics.
Alterity Therapeutics received 158 more outperform votes than Galecto when rated by MarketBeat users. However, 58.82% of users gave Galecto an outperform vote while only 57.67% of users gave Alterity Therapeutics an outperform vote.
Alterity Therapeutics' return on equity of 0.00% beat Galecto's return on equity.
Alterity Therapeutics has higher revenue and earnings than Galecto. Alterity Therapeutics is trading at a lower price-to-earnings ratio than Galecto, indicating that it is currently the more affordable of the two stocks.
Alterity Therapeutics has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, Galecto has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.
In the previous week, Galecto had 3 more articles in the media than Alterity Therapeutics. MarketBeat recorded 3 mentions for Galecto and 0 mentions for Alterity Therapeutics. Galecto's average media sentiment score of 1.22 beat Alterity Therapeutics' score of 0.00 indicating that Galecto is being referred to more favorably in the news media.
Summary
Galecto beats Alterity Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Alterity Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRAN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alterity Therapeutics Competitors List
Related Companies and Tools
